Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al.
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. McConnell JD, Bruskewitz R, Walsh P, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. 42(4):558-63.īell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, et al. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. 46 (6):601-7.Ĭantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, Hemerson P, Rogers M, Stamper B. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. 22 (16):5077-5081.Įmberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia. Zhou B, Wang P, Xu WJ, Li YM, Tong DL, Jiang J, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men. Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong H, et al. Current Status of the Relationship Between Metabolic Syndrome and Lower Urinary Tract Symptoms. Public Health Service, US Department of Health and Human Services, 1994. Rockville, Md: Agency for Healthcare Policy and Research. Benign Prostatic Hyperplasia: Diagnosis and Treatment. McConnell JD, Barry MJ, Bruskewitz RC, et al. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. NovemAccessed: February 19, 2021.ĭ'Silva KA, Dahm P, Wong CL.
American Cancer Society recommendations for prostate cancer early detection. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial. 62(4):614-22.Ĭarballido J, Fourcade R, Pagliarulo A, et al. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty. Seftel AD, Rosen RC, Rosenberg MT, Sadovsky R. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension?. Benign Prostatic Hyperplasia: Review of Modern Minimally Invasive Surgical Treatments. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ. Transurethral Resection of the Prostate.Phytotherapeutic Agents and Dietary Supplements.American Urological Association Guidelines.
0 kommentar(er)
